147 related articles for article (PubMed ID: 28461099)
21. The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.
Matsuo NCA; Ando H; Doi Y; Shimizu T; Ishima Y; Ishida T
Chem Pharm Bull (Tokyo); 2022; 70(5):351-358. PubMed ID: 35491191
[TBL] [Abstract][Full Text] [Related]
22. A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.
Ando H; Fukushima M; Eshima K; Hasui T; Shimizu T; Ishima Y; Huang CL; Wada H; Ishida T
Cancer Med; 2019 Dec; 8(17):7313-7321. PubMed ID: 31609087
[TBL] [Abstract][Full Text] [Related]
23. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Nagao A; Abu Lila AS; Ishida T; Kiwada H
Int J Pharm; 2013 Jan; 441(1-2):395-401. PubMed ID: 23174409
[TBL] [Abstract][Full Text] [Related]
25. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA.
Hattori Y; Arai S; Kikuchi T; Ozaki KI; Kawano K; Yonemochi E
J Drug Target; 2016 Apr; 24(4):309-317. PubMed ID: 26234899
[TBL] [Abstract][Full Text] [Related]
27. Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.
Doi Y; Abu Lila AS; Matsumoto H; Okada T; Shimizu T; Ishida T
Int J Nanomedicine; 2016; 11():5573-5582. PubMed ID: 27822036
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma.
Yang C; Liu HZ; Fu ZX; Lu WD
BMC Biotechnol; 2011 Mar; 11():21. PubMed ID: 21401960
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
30. PEG-liposomal oxaliplatin combined with nuclear factor-κB inhibitor (PDTC) induces apoptosis in human colorectal cancer cells.
Yang C; Fu ZX
Oncol Rep; 2014 Oct; 32(4):1617-21. PubMed ID: 25174808
[TBL] [Abstract][Full Text] [Related]
31. Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose.
Nakamura H; Abu Lila AS; Nishio M; Tanaka M; Ando H; Kiwada H; Ishida T
J Control Release; 2015 Dec; 220(Pt A):406-413. PubMed ID: 26548975
[TBL] [Abstract][Full Text] [Related]
32. B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice.
Hashimoto Y; Abu Lila AS; Shimizu T; Ishida T; Kiwada H
J Control Release; 2014 Jun; 184():1-8. PubMed ID: 24727075
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery.
Wang Z; Jay CM; Evans C; Kumar P; Phalon C; Rao DD; Senzer N; Nemunaitis J
Toxicol Sci; 2017 Feb; 155(2):400-408. PubMed ID: 27815492
[TBL] [Abstract][Full Text] [Related]
34. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model.
Juul CA; Engel TB; Fliedner FP; Ringgaard L; Eliasen R; Melander F; Bak M; Kjær A; Henriksen JR; Elema DR; Hansen AE; Andresen TL
J Control Release; 2024 Jul; 371():288-297. PubMed ID: 38705519
[TBL] [Abstract][Full Text] [Related]
35. Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors.
Song F; Sakurai N; Okamoto A; Koide H; Oku N; Dewa T; Asai T
Biol Pharm Bull; 2019; 42(6):996-1003. PubMed ID: 31155597
[TBL] [Abstract][Full Text] [Related]
36. [Elucidation for Intratumor Localization of a DDS-based Anticancer Drug and Enhancement of Its Therapeutic Effects via Improvement of the Tumor Microenvironment].
Ando H
Yakugaku Zasshi; 2021; 141(11):1241-1245. PubMed ID: 34719544
[TBL] [Abstract][Full Text] [Related]
37. Revisiting the use of sPLA
Pourhassan H; Clergeaud G; Hansen AE; Østrem RG; Fliedner FP; Melander F; Nielsen OL; O'Sullivan CK; Kjær A; Andresen TL
J Control Release; 2017 Sep; 261():163-173. PubMed ID: 28662900
[TBL] [Abstract][Full Text] [Related]
38. An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
Ando H; Ishida T
Adv Drug Deliv Rev; 2020; 154-155():27-36. PubMed ID: 32781056
[TBL] [Abstract][Full Text] [Related]
39. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcyclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Fu H; Zhang Z; He Q
J Pharm Sci; 2015 Feb; 104(2):476-84. PubMed ID: 25256603
[TBL] [Abstract][Full Text] [Related]
40. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
